The short version.
If you've researched AOD-9604, you've probably seen it discussed in stacks — typically alongside a GH-secretagogue (sermorelin or CJC-1295/ipamorelin) or a mitochondrial peptide (MOTS-C). The logic: AOD targets adipocyte lipolysis; the secretagogue raises endogenous GH pulses, which themselves have lipolytic and recomp effects; MOTS-C operates on mitochondrial energetics and insulin sensitivity.
The case for stacking is that the mechanisms don't overlap. The case against is that stacking compresses signal — when something works or doesn't, you can't tell which compound is responsible. More on peptide stacking →
What people actually pair with AOD.
| Pairing | Stated rationale | Honest caveat |
|---|---|---|
| AOD + sermorelin | Lipolysis (AOD) + endogenous GH pulse restoration (sermorelin) | Mechanisms differ; combined lipolytic effect not well-characterized in trials |
| AOD + CJC-1295 / ipamorelin | Lipolysis + sustained GHRH analog + GH-pulse amplifier | More moving parts; harder to attribute outcomes |
| AOD + MOTS-C | Lipolysis + mitochondrial / insulin-sensitivity angle | MOTS-C human data is early; combined effect unproven |
| AOD + tirzepatide | Adipocyte lipolysis adjunct alongside GLP-1/GIP appetite control | Most users get the bulk of weight change from tirzepatide alone |
The honest framing: AOD-9604's underlying human evidence is modest. Stacking it with a more evidence-supported compound (a GLP-1, or a GH-secretagogue with longer use history) can dilute attribution and complicate dose adjustment. The stack you can interpret is usually better than the stack that "hits everything."
The stack you can interpret is usually better than the stack that hits everything.
Why oversight matters.
The internet sells almost any peptide as research chemicals — vials with disclaimers, no prescription, no provider, no follow-up. The risk isn't theoretical. Sterility, peptide identity, peptide content, and contamination all vary widely between gray-market vendors. The FDA has been explicit that compounded drugs aren't FDA-approved, and that research-only labels don't protect consumers when products end up in human use.
Oversight isn't a bureaucratic checkbox. It's a U.S.-licensed prescriber who reviews your history before prescribing, a 503A compounding pharmacy that sources active pharmaceutical ingredient and prepares the medication under USP 797 sterile standards, and a follow-up cadence that lets someone catch a problem before it becomes a worse one.
How Boswell handles this.
Boswell pairs you with a U.S.-licensed physician for the intake. They review your goals, medications, history, and any contraindications before prescribing. If a protocol isn't appropriate, you don't get it. If it is, the prescription goes to a 503A compounding pharmacy that prepares the medication under sterile compounding standards, labels it for you specifically, and ships it directly.
Refills aren't automatic — they involve a check-in. The point isn't to gate access; it's to keep someone clinical in the loop while you're on therapy. How Boswell works →
Questions worth asking your provider.
- If I'm new to peptides, should I run AOD alone first to establish a baseline?
- What's the case for adding sermorelin or CJC/ipa rather than running them sequentially?
- How would we tell which compound is doing the work — or not?
- What's the simplest stack that still addresses my goals?
- What's the off-ramp if I want to taper one and keep another?
Sources